Korea BNC and ProAbtek jointly develop Albubody’s dual-target next-generation ADC anticancer drug

CAR-T Digest - August 2020

05 December 2025: Korea BNC and ProAbtek jointly develop Albubody’s dual-target next-generation ADC anticancer drug

Korea BNC and ProAbTech signed a joint R&D deal to develop dual-target ADCs powered by Albubody, a long-acting antibody-fragment platform with strong tumor penetration
Albubody extends half-life over 200-fold and, when paired with the SelecAll bioconjugation system, enables precise payload attachment without affecting antigen binding
This approach has already shown promise, with a HER2-targeting Albubody drug conjugate delivering ~90% tumor inhibition in xenograft models while maintaining tolerability
Leveraging these results, both companies have screened multiple dual-target options and selected two priority combinations for next-stage ADC development
The collaboration will now focus on designing two bispecific Albubody-based ADC candidates and establishing PoC through PK/PD studies, supported by a newly filed joint patent